Klinische Wochenschrift

, Volume 68, Issue 16, pp 814–822

Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia

Authors

  • J. Thiery
    • Institut für Klinische Chemie am Klinikum Großhadern der Ludwig-Maximilians-Universität
  • C. Creutzfeldt
    • Abteilung für Gastroenterologie and EndokrinologieZentrum Innere Medizin, Klinikum Göttingen
  • W. Creutzfeldt
    • Abteilung für Gastroenterologie and EndokrinologieZentrum Innere Medizin, Klinikum Göttingen
  • A. K. Walli
    • Institut für Klinische Chemie am Klinikum Großhadern der Ludwig-Maximilians-Universität
  • D. Seidel
    • Institut für Klinische Chemie am Klinikum Großhadern der Ludwig-Maximilians-Universität
Originals

DOI: 10.1007/BF01796271

Cite this article as:
Thiery, J., Creutzfeldt, C., Creutzfeldt, W. et al. Klin Wochenschr (1990) 68: 814. doi:10.1007/BF01796271

Summary

We investigated long-term hypolipidemic effects and clinical safety of simvastatin, a new competitive inhibitor of 3-hydroxy-methylglutaryl coenzyme A reductase in 24 patients with familial and non-familial hypercholesterolemia. Patients received up to 40 mg simvastatin for a period of 30 months. Significant decreases were noted in plasma cholesterol (30%), plasma triglycerides (25%), very low density lipoprotein-cholesterol (26%), and low density lipoprotein-cholesterol (40%), whereas an increase in plasma high density lipoprotein-cholesterol (11%) was observed. Furthermore, the percentage decrease in plasma low density lipoprotein cholesterol was independent of individual baseline concentrations. Simvastatin did not alter the composition of low density lipoproteins or high density lipoproteins. The percentage decrease in total plasma and low density lipoprotein-cholesterol was independent of apoprotein E isoforms and low density lipoprotein-receptor activity as assayed in cultured fibroblasts. The drug therapy was well tolerated and clinical examinations revealed no adverse effects. Clinical chemistry indices and hematological, as well as endocrinological parameters remained within normal limits and ranges.

Key words

HypercholesterolemiaLipoproteinsSimvastatinHormones

Abbreviations

VLDL

very low density lipoprotein

LDL

low density lipoprotein

HDL

high density lipoprotein

CHD

coronary heart disease

LDL-C

low density lipoprotein-cholesterol

FH

familial hypercholesterolemia

HMG-CoA

3-hydroxy-3-methylglutaryl-coenzyme A

HELP

heparin extracorporeal low density lipoprotein precipitation

Copyright information

© Springer-Verlag 1990